|
시장보고서
상품코드
2083879
해부 병리학 시장 : 제품별, 기술별, 워크플로우 단계별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)Anatomic Pathology Market by Product, Technology, Workflow Stage, Application, End User - Global Forecast 2026-2032 |
||||||
360iResearch
해부 병리학 시장은 2032년까지 연평균 복합 성장률(CAGR) 8.98%로 성장해 754억 3,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 412억 9,000만 달러 |
| 추정 연도(2026년) | 448억 달러 |
| 예측 연도(2032년) | 754억 3,000만 달러 |
| CAGR(%) | 8.98% |
해부 병리학은 암 진단, 조직을 통한 질환의 특성 평가, 이식 평가, 염증성 질환 검사, 정밀 의학의 핵심을 이루고 있습니다. 이 부문은 조직병리학, 세포병리학, 면역조직화학, in situ 하이브리드화, 분자병리학, 부검병리학, 외과병리학의 워크플로우를 통해 조직 검체를 임상적으로 활용 가능한 진단 결과로 변환합니다.
수요는 암 발병률 증가, 고령화, 바이오마커 중심의 암 치료가 지속적으로 확대됨에 따라 구조적으로 뒷받침되고 있습니다. 국제암연구소(IARC)의 보고에 따르면, 2022년에는 전 세계적으로 약 2,000만 건의 신규 암 사례와 970만 건의 암 사망이 확인되었으며, 조기 발견, 종양 분류, 병기 분류, 악성도 분류, 치료법 선택에 있어 병리 검사실이 수행하는 필수적인 역할이 다시금 부각되고 있습니다.
또한, 디지털 병리학, 검사실 자동화, 동반 진단, 인공지능(AI)을 활용한 영상 분석을 바탕으로 시장이 재편되고 있습니다. 검체 수가 증가하고, 지역에 따라 분야별 전문 지식의 분포에 편차가 있는 가운데, 의료 시스템 및 진단 네트워크에서는 검사 결과 보고까지 소요되는 시간, 품질 보증, 병리 전문의의 생산성, 통합 보고서, 조직 관리가 우선 과제로 대두되고 있습니다.
해부 병리학 분야의 획기적인 변화
해부 병리학에서 가장 중요한 변화는 현미경 중심의 업무 흐름에서 데이터가 풍부한 진단 생태계로의 전환입니다. 전체 슬라이드 이미징, 검사 정보 시스템, 이미지 관리 플랫폼, 상호 운용 가능한 보고 도구를 통해 분산형 네트워크를 통한 원격 심사, 종양 회진, 교육, 아카이브, 품질 관리가 가능해졌습니다.
해부 병리학 분야에서 인공지능이 미치는 누적 영향
인공지능은 병리의를 대체하는 것이 아니라, 해부 병리학 전반에 누적적인 가치를 가져다주고 있습니다. AI를 활용한 도구는 증례의 우선순위 지정, 유사분열 수 계수, 종양 감지, 바이오마커 정량화, 품질 검사, 업무 부하 균형 조정, 전체 슬라이드 이미지에서 연구 수준의 특성 추출 등에 활용되고 있습니다.
세계 해부 병리학 분야의 주요 지역별 동향
북미는 암 검진 보급률이 높고, 성숙한 병원 네트워크, 대규모 참조 실험실, CAP 인증 품질 관리 시스템, 디지털 병리학의 조기 도입 등을 바탕으로 해부 병리학 분야의 주요 지역으로 자리매김하고 있습니다. 미국은 종양 진단, 대학 병원, 실험실 개발 검사(LDT)에 대한 전문 지식, 그리고 참조 실험실 네트워크를 통해 이 지역의 성장 동력을 주도하고 있습니다. 한편, 캐나다는 공적 자금을 통한 암 치료 경로, 주 차원의 병리학 현대화, 품질에 기반한 진단 접근성을 중시하고 있습니다.
해부 병리학 시장의 주요 그룹별 분석
인도네시아, 태국, 베트남, 말레이시아, 필리핀, 싱가포르가 병원의 수용 능력과 암 의료 네트워크를 확대함에 따라 아세안(ASEAN)의 중요성이 커지고 있습니다. 싱가포르는 정밀 진단, 디지털 헬스, 임상 연구 분야의 지역 허브 역할을 수행하고 있지만, 더 광범위한 아세안(ASEAN) 시장에서는 비용 효율성, 인력 부족, 품질 표준화, 지방 도시에서 중앙 검사실로 검체를 운송하는 문제 등 다양한 과제를 해결할 수 있는 확장성이 뛰어난 병리학 솔루션이 요구되고 있습니다.
해부 병리학 분야의 주요 국가에 대한 분석
미국은 대규모 암 의료 네트워크, 민간 및 학술계 참조 실험실, CLIA 인증 검사, CAP 인증, 동반 진단의 적극적인 도입에 힘입어 가장 영향력 있는 국가 시장이 되었습니다. 캐나다는 통합된 암 프로그램, 주별 품질 기준, 공정한 진단 경로를 우선시하고 있습니다. 한편, 멕시코와 브라질은 광활하고 지리적으로 다양한 전체 인구를 대상으로 증가하는 종양학 분야 수요에 대응하기 위해 민간 및 공공 진단 체계를 확충하고 있습니다.
해부 병리학 분야 리더를 위한 실천적 제안
산업계의 리더는 개별적인 기술 도입보다는 종단 간 워크플로우의 현대화를 우선시해야 합니다. 성공적인 프로그램에서는 검체 추적, 육안 소견, 조직 처리, 염색, 슬라이드 스캔, 보고, 보관, 품질 관리를 연계하여 생산성, 소요 시간, 진단 품질과 같은 측정 가능한 성과로 이어지게 하고 있습니다.
해부 병리학 분석을 위한 조사 기법
본 요약본은 세계보건기구(WHO), 국제암연구소(IARC), 미국 식품의약국(FDA), 메디케어·메디케이드 서비스 센터(CMS), 미국 병리학 협회(CAP), 유럽 위원회, 각국의 암 대책 기관, 동료 심사를 거친 문헌, 주요 의료 시스템의 간행물 등 공개된 권위 있는 정보원을 바탕으로 한 2차 조사에 근거하고 있습니다.
결론 : 해부 병리학의 미래
해부 병리학은 주로 수작업에 의존하던 진단 방식에서 벗어나, 디지털 기술을 활용하여 바이오마커 중심의 정밀 의학의 기반으로 진화하고 있습니다. 암 발병률 증가, 조직 검사의 확대, 보다 신속하고 재현성이 높은 진단에 대한 수요 증가로 인해, 의료 시스템 전반에서 그 역할은 점점 더 중요해지고 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 해부 병리학 시장 : 제품별
제8장 해부 병리학 시장 : 기술별
제9장 해부 병리학 시장 : 워크플로우 단계별
제10장 해부 병리학 시장 : 용도별
제11장 해부 병리학 시장 : 최종 사용자별
제12장 해부 병리학 시장 : 지역별
제13장 해부 병리학 시장 : 그룹별
제14장 해부 병리학 시장 : 국가별
제15장 경쟁 구도
제16장 기업 개요
KTH 26.07.20The Anatomic Pathology Market is projected to grow by USD 75.43 billion at a CAGR of 8.98% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 41.29 billion |
| Estimated Year [2026] | USD 44.80 billion |
| Forecast Year [2032] | USD 75.43 billion |
| CAGR (%) | 8.98% |
Anatomic pathology sits at the center of cancer diagnosis, tissue-based disease characterization, transplant evaluation, inflammatory disease workups, and precision medicine. The discipline spans histopathology, cytopathology, immunohistochemistry, in situ hybridization, molecular pathology, autopsy pathology, and surgical pathology workflows that convert tissue specimens into clinically actionable diagnoses.
Demand is structurally supported by rising cancer incidence, aging populations, and the continued expansion of biomarker-driven oncology. The International Agency for Research on Cancer reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, reinforcing the indispensable role of pathology laboratories in early detection, tumor classification, staging, grading, and therapy selection.
The market is also being reshaped by digital pathology, laboratory automation, companion diagnostics, and artificial intelligence-enabled image analysis. Health systems and diagnostic networks are prioritizing turnaround time, quality assurance, pathologist productivity, integrated reporting, and tissue stewardship as specimen volumes increase and subspecialty expertise remains unevenly distributed across geographies.
Transformative Shifts in the Anatomic Pathology Landscape
The most important shift in anatomic pathology is the movement from microscope-centered workflows to data-rich diagnostic ecosystems. Whole slide imaging, laboratory information systems, image management platforms, and interoperable reporting tools are enabling remote review, tumor boards, education, archiving, and quality control across distributed networks.
Precision oncology is another major force. Immunohistochemistry, fluorescence in situ hybridization, next-generation sequencing triage, and companion diagnostic testing are increasingly embedded in routine tissue workflows. This is raising expectations for standardized pre-analytics, validated assays, tissue stewardship, and faster reflex testing pathways that preserve limited biopsy material.
Regulation is becoming more consequential. In the United States, CLIA oversight, College of American Pathologists accreditation, and the FDA's 2024 final rule on laboratory developed tests are influencing validation, documentation, and risk management. In Europe, the In Vitro Diagnostic Regulation is reshaping conformity assessment and evidence expectations for diagnostic products used in pathology laboratories.
Cumulative Impact of Artificial Intelligence in Anatomic Pathology
Artificial intelligence is adding cumulative value across anatomic pathology rather than replacing pathologists. AI-assisted tools are being applied to case prioritization, mitotic counting, tumor detection, biomarker quantification, quality checks, workload balancing, and research-grade feature extraction from whole slide images.
Regulatory milestones have validated the clinical direction of the field. The U.S. Food and Drug Administration authorized the first whole slide imaging system for primary diagnostic use in 2017, and subsequent clearances for AI-assisted pathology applications have demonstrated growing acceptance of software as a medical device when supported by analytical and clinical validation.
The cumulative impact is operational and clinical. AI can reduce repetitive measurement burden, flag regions of interest, improve reproducibility in quantitative assays, and support subspecialty consultation in underserved areas. However, adoption depends on scanner standardization, data governance, cybersecurity, algorithm monitoring, bias assessment, pathologist oversight, and clear reimbursement or productivity justification.
Key Regional Insights Across Global Anatomic Pathology
North America remains a leading region for anatomic pathology because of high cancer screening uptake, mature hospital networks, reference laboratory scale, CAP-accredited quality systems, and early adoption of digital pathology. The United States drives much of the regional momentum through oncology diagnostics, academic medical centers, laboratory developed testing expertise, and reference laboratory networks, while Canada emphasizes publicly funded cancer care pathways, provincial pathology modernization, and quality-based diagnostic access.
Europe combines strong academic pathology expertise with regulatory transformation under the EU In Vitro Diagnostic Regulation. Germany, France, Italy, Spain, and the United Kingdom are advancing cancer diagnostics, biobanking, digital health infrastructure, and genomics-enabled care, although procurement cycles, workforce pressures, and data protection requirements can slow implementation. Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN health systems address growing cancer burdens, urban hospital capacity, organized screening initiatives, and the need for standardized pathology quality.
Latin America, the Middle East, and Africa show rising need for tissue diagnostics tied to oncology expansion, infectious disease pathology, and increasing use of immunohistochemistry and molecular testing, but access remains uneven. Brazil and Mexico anchor Latin American demand through large public and private healthcare networks, Middle Eastern countries are investing in tertiary care, oncology centers, and laboratory accreditation, and African markets are focused on workforce development, sample logistics, external quality assessment, and regional reference testing models to improve access to reliable anatomic pathology services.
Key Group Insights for Anatomic Pathology Markets
ASEAN is gaining importance as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore expand hospital capacity and cancer care networks. Singapore acts as a regional hub for advanced diagnostics, digital health, and clinical research, while larger ASEAN markets require scalable pathology solutions that address affordability, workforce shortages, quality standardization, and specimen transport from secondary cities to centralized laboratories.
The GCC is investing in advanced tertiary care, oncology centers, laboratory accreditation, and digital health platforms, making it a significant corridor for premium pathology instrumentation, outsourced diagnostic partnerships, and quality-led modernization. The European Union is shaped by IVDR compliance, cross-border research programs, cancer mission initiatives, and strong public health systems, creating demand for validated diagnostics, traceable workflows, interoperable data systems, and evidence-based digital pathology adoption.
BRICS countries represent high-volume pathology environments because Brazil, Russia, India, China, and South Africa combine large patient populations with expanding oncology infrastructure and variable access to subspecialty expertise. G7 markets remain innovation leaders in digital pathology, molecular integration, clinical validation, and AI governance. NATO countries overlap substantially with advanced North American and European diagnostic systems, where resilience, cybersecurity, continuity planning, and secure medical data infrastructure are increasingly relevant to laboratory modernization.
Key Country Insights in Anatomic Pathology
The United States is the most influential country market, supported by large cancer care networks, commercial and academic reference laboratories, CLIA-certified testing, CAP accreditation, and strong adoption of companion diagnostics. Canada prioritizes centralized cancer programs, provincial quality standards, and equitable diagnostic pathways, while Mexico and Brazil are expanding private and public diagnostic capacity to address rising oncology needs across large and geographically diverse populations.
In Europe, the United Kingdom has invested in genomics, cancer diagnostic capacity, and digital pathology initiatives through the National Health Service, while Germany benefits from advanced laboratory infrastructure, strong medical technology adoption, and established pathology expertise. France, Italy, and Spain combine universal health systems with active cancer screening, hospital-based pathology networks, and increasing interest in molecular pathology, while Russia maintains demand through large tertiary hospitals and oncology centers despite procurement and geopolitical constraints.
China and India are high-priority anatomic pathology markets due to large disease burdens, hospital expansion, growing cancer screening activity, and increasing use of immunohistochemistry, histochemistry, and molecular pathology. Japan and South Korea are advanced markets with strong cancer diagnostics, automation, digital health capacity, and precision medicine infrastructure, while Australia benefits from organized cancer screening, high-quality pathology standards, accreditation culture, and regional leadership in digital health implementation.
Actionable Recommendations for Anatomic Pathology Leaders
Industry leaders should prioritize end-to-end workflow modernization rather than isolated technology purchases. Successful programs link specimen tracking, grossing, tissue processing, staining, slide scanning, reporting, archiving, and quality management into measurable productivity, turnaround time, and diagnostic quality outcomes.
Vendors and laboratories should invest in regulatory-grade validation, cybersecurity, interoperability, and pathologist-centered design. AI deployment should begin with high-value use cases such as triage, quality control, biomarker quantification, and workload optimization, with post-implementation monitoring, documented performance metrics, and transparent governance.
Commercial strategies should be region-specific. Mature markets need differentiated digital pathology platforms, automation, integrated molecular workflows, and evidence-based AI, while emerging markets need affordable instruments, training, remote consultation networks, external quality assessment, and accredited reference laboratory partnerships that improve access without compromising diagnostic quality.
Research Methodology for Anatomic Pathology Analysis
This executive summary is based on secondary research from publicly available and authoritative sources, including the World Health Organization, International Agency for Research on Cancer, U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, College of American Pathologists, European Commission, national cancer agencies, peer-reviewed literature, and major health system publications.
The analysis evaluates market drivers, regulatory developments, technology adoption, regional health infrastructure, workforce considerations, and country-level diagnostic capacity. Insights were cross-checked against recognized clinical and policy references to avoid unsupported assumptions and to ensure that the conclusions reflect verifiable trends in anatomic pathology, digital pathology, AI-enabled diagnostics, laboratory automation, and precision oncology.
Conclusion: The Future of Anatomic Pathology
Anatomic pathology is evolving from a predominantly manual diagnostic specialty into an integrated, digitally enabled, and biomarker-driven foundation of precision medicine. Rising cancer incidence, expanding tissue-based testing, and growing demand for faster and more reproducible diagnoses are strengthening its role across healthcare systems.
The next phase of leadership will favor organizations that combine scientific rigor, workflow efficiency, regulatory readiness, interoperability, and responsible AI adoption. Laboratories, technology vendors, and healthcare providers that align innovation with quality, access, data security, and clinical trust will be best positioned to create long-term value in global anatomic pathology.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anatomic Pathology Market, by Product
- 7.1. Instruments & Equipment
- 7.1.1. Slide-Staining Systems
- 7.1.2. Tissue Processing Systems
- 7.1.3. Embedding Systems
- 7.1.4. Microtomes
- 7.1.5. Pathology Scanners
- 7.1.6. Microscopes
- 7.1.7. Grossing Stations
- 7.1.8. Tissue Homogenizers
- 7.2. Reagents & Consumables
- 7.2.1. Antibodies & Reagents
- 7.2.2. Kits
- 7.2.3. Slides & Coverslips
- 7.2.4. Cassettes & Embedding Media
- 7.3. Services
- 7.3.1. Reference Laboratory Services
- 7.3.2. Maintenance & Support
- 7.4. Software & Analysis Tools
- 7.4.1. Image Analysis Software
- 7.4.2. Laboratory Information Systems
- 7.4.3. Pathology Viewers
8. Anatomic Pathology Market, by Technology
- 8.1. Digital Pathology
- 8.2. Immunohistochemistry
- 8.3. In Situ Hybridization
- 8.4. Molecular Diagnostics
- 8.5. Special Staining
9. Anatomic Pathology Market, by Workflow Stage
- 9.1. Specimen Pre-Analytics
- 9.2. Tissue Processing & Embedding
- 9.3. Microtomy
- 9.4. Staining & Labeling
- 9.5. Image Analysis
- 9.6. Interpretation & Reporting
10. Anatomic Pathology Market, by Application
- 10.1. Disease Diagnosis
- 10.1.1. Cancer
- 10.1.2. Infectious Diseases
- 10.1.3. Neurological Disorders
- 10.1.4. Cardiovascular Diseases
- 10.2. Drug Discovery & Development
- 10.3. Academic & Research
11. Anatomic Pathology Market, by End User
- 11.1. Hospitals
- 11.2. Diagnostic Laboratories
- 11.3. Ambulatory Surgical Centers
- 11.4. Pharmaceuticals & Biotechnology Companies
- 11.5. Academic & Research Institutes
12. Anatomic Pathology Market, by Region
- 12.1. Asia-Pacific
- 12.2. North America
- 12.3. Latin America
- 12.4. Europe
- 12.5. Middle East
- 12.6. Africa
13. Anatomic Pathology Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
14. Anatomic Pathology Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
15. Competitive Landscape
- 15.1. Market Concentration Analysis, 2025
- 15.1.1. Concentration Ratio (CR)
- 15.1.2. Herfindahl Hirschman Index (HHI)
- 15.2. Recent Developments & Impact Analysis, 2025
- 15.3. Product Portfolio Analysis, 2025
- 15.4. Benchmarking Analysis, 2025
16. Company Profiles
- 16.1. F. Hoffmann-La Roche Ltd
- 16.2. Danaher Corporation
- 16.3. Labcorp Holdings Inc.
- 16.4. Sonic Healthcare Limited
- 16.5. Quest Diagnostics Incorporated
- 16.6. Agilent Technologies, Inc.
- 16.7. SYNLAB AG
- 16.8. PHC Holdings Corporation
- 16.9. Siemens Healthineers AG
- 16.10. BIOMERIEUX
- 16.11. Neogenomics Laboratories, Inc.
- 16.12. Sysmex Corporation
- 16.13. Abbott Laboratories
- 16.14. Hologic, Inc.
- 16.15. ARUP Laboratories
- 16.16. Avantik
- 16.17. Bio-Techne Corporation
- 16.18. Biocare Medical, LLC
- 16.19. Cardinal Health
- 16.20. Cell Signaling Technology, Inc.
- 16.21. Cerba Research NV
- 16.22. Charles River Laboratories International, Inc.
- 16.23. Epredia
- 16.24. FUJIFILM Holdings Corporation
- 16.25. GPI S.p.A.
- 16.26. Guardant Health, Inc.
- 16.27. Healthscope Ltd.
- 16.28. Inpeco SA
- 16.29. Koninklijke Philips N.V.
- 16.30. LigoLab Information Systems
- 16.31. Milestone SPA
- 16.32. Molecular Pathology Laboratory Network, Inc.
- 16.33. Propath UK Limited
- 16.34. Proscia Inc.
- 16.35. Sakura Seiki Co., Ltd.
- 16.36. Techcyte, Inc.
- 16.37. Unilabs SA
- 16.38. Veracyte, Inc.
- 16.39. Visiant Health
